Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

235.61 +4.08 (+1.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corp

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years
From Insulet Corporation
Via Business Wire
Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
From Insulet Corporation
Via Business Wire
Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia
From Insulet Corporation
Via Business Wire
Expert Ratings for Insulet
Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings: 
Via Benzinga
Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks
The deal would have been transformative, but may have limited teamwork in the space. 
Via Investor's Business Daily
Looking Into Insulet's Return On Capital Employed
According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4. 
Via Benzinga
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space
One analyst called the rumored deal "transformative," but says the timing is unfavorable. 
Via Investor's Business Daily
PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition
Insulet (PODD) stock is heading higher on Tuesday as investors react to reports that DexCom (DXCM) is considering acquiring the company. 
Via InvestorPlace
Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning! 
Via InvestorPlace
Citigroup Maintains Buy Rating for Insulet: Here's What You Need To Know
Citigroup has decided to maintain its Buy rating of Insulet (NASDAQ:PODD) and lower its price target from $350.00 to $310.00. Shares of Insulet are trading up 1.23% over the last 24 hours, at $199.34... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday. 
Via Benzinga
Recap: Insulet Q1 Earnings
Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by... 
Via Benzinga
Insulet Announces CEO Transition
From Insulet Corporation
Via Business Wire
Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet’s 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose
From Insulet Corporation
Via Business Wire
Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes
Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with... 
Via Benzinga
Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes
From Insulet Corporation
Via Business Wire
Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022
From Insulet Corporation
Via Business Wire
Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%
Insulet Corp's (NASDAQ: PODD) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million, exceeding the consensus of $301.06 million. The company... 
Via Benzinga
Recap: Insulet Q4 Earnings
Insulet (NASDAQ:PODD) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet... 
Via Benzinga
Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year
From Insulet Corporation
Via Business Wire
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
Insulet Promotes Inclusivity for People with Diabetes through Nintendo® Video Game Animal Crossing™: New Horizons
From Insulet Corporation
Via Business Wire
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine
From Insulet Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.